IRTCiRhythm Holdings, Inc.

Filed with the SEC on November 5, 2026 | Form 10-Q | Price: $90.65 | Today's Change: -30.37%

---

What Happened

iRhythm Technologies (IRTC) filed its quarterly report (Form 10-Q) with the SEC on November 5, 2026, disclosing results for the third quarter of fiscal year 2026. Revenue came in at $538.2 million, while the company reported a net loss of $30.7 million, or $1.57 per share (basic and diluted). The operating loss for the quarter was $59.7 million, underscoring that the company continues to invest heavily in its operations while losses at the operating line remain substantial.

---

Why It Matters

For investors, the core tension in this filing is familiar: iRhythm is generating meaningful and growing revenue at scale, but operational costs continue to outpace the top line in terms of profitability conversion. The $59.7 million operating loss relative to $538.2 million in revenue implies an operating margin that remains deeply negative, raising near-term questions about the pace and credibility of the company's path to profitability. The market's reaction — a single-session decline of over 30% — signals that investors may have held expectations that the actual results did not meet, whether on profitability trajectory, margin improvement, or forward guidance not captured in the structured filing data provided here. StockWatch initiated coverage of IRTC on September 23, 2026, and this quarterly print represents a significant data point against the backdrop of that existing research.

Key figures at a glance:

• Revenue (Q3 FY2026): $538,248,000
• Net Loss (Q3 FY2026): -$30,700,000
• EPS (Basic & Diluted): -$1.57
• Operating Loss (Q3 FY2026): -$59,693,000
• Stock Decline (Day of Report): -30.37%

---

Analysis

The scale of today's selloff — approaching a third of the company's market value wiped out in a single session — is a signal that this quarterly report delivered a meaningful negative surprise to market participants. The structured data alone does not reveal whether that surprise stems from a revenue miss, a wider-than-expected loss, or disappointing forward guidance, as guidance figures are not captured in the XBRL data provided. What the numbers do confirm is that at a $538 million quarterly revenue run rate, iRhythm remains a substantial commercial operation in the cardiac monitoring space, yet operating losses of nearly $60 million in a single quarter indicate that the cost structure has not yet bent sufficiently toward profitability.

Investors and analysts will want to scrutinize the full 10-Q narrative — particularly any management commentary on reimbursement trends, sales force productivity, and the gross margin trajectory — to understand whether this quarter represents a one-time setback or a structural challenge. The divergence between the top-line scale and the depth of operating losses is the central question the company will need to answer convincingly in the quarters ahead.

---

Disclaimer

This report is a news and informational analysis based solely on data extracted from iRhythm's SEC filing and publicly available market data. It does not constitute investment advice, an offer or solicitation to buy or sell any security, or an equity research recommendation. No rating or price target is issued or implied herein. Investors should conduct their own due diligence and consult a qualified financial professional before making investment decisions.

Existing Coverage

StockWatch has full coverage on IRTC, published 2026-09-23. Read our Initiating Coverage →

Source

Filed with the SEC on 2026-11-05. Read the original filing on EDGAR: https://www.sec.gov/Archives/edgar/data/1388658/000138865826000094/irtc-20260930.htm